# Supplementary Figure 1




**Supplementary Figure 1. Localization of Injected MSC and CCR2+ Monocytes in the Recipients' Lung.** CCR2-GFP reporter mice (n=3 per group) were administered $2x10^5$ MSC labeled with Cell Tracker Orange by the i.v. route and pulmonary $CCR2^+$ monocyte responses were assessed at various time points after injection using confocal microscopy. In (**A**), numerous Cell Tracker Orange positive MSC were detected in lung tissues throughout the observation period. Panels: 0, 8, 24, and 72 hours after MSC injection. Following MSC injection (**B**), large numbers of $CCR2\text{-}GFP^+$ cells appeared in the lungs within 8 hours of injection, and persisted throughout the 7 days observation period. Panels: 8, 24, and 72 hours, and 7 days after MSC injection. Right 2 panels represented 24 hours after vehicle or MSC injection in larger magnifications.

# Supplementary Figure 2




**Supplementary Figure 2. Effects of MSC Administration on Treg Populations in Lungs of Allergen Sensitized and Challenged Mice.** WT mice were sensitized and challenged with OVA. Prior to the first OVA challenge, mice received PBS alone (Vehicle) or MSC (MSC) by i.v. injection as described in Methods. Twenty-four hours after the last OVA challenge, lung cells were analyzed for $GFP^{+}CD4^{+}$ cells per total lung CD4+ cells (n=4 per group) (*$p< 0.05$).

# Supplementary Figure 3

(A)




(B)




**Supplementary Figure 3. Effects of Liposome Clodronate (LC) on MSC (A) and Macrophages (B).** MSC and primary bone marrow derived macrophages were seeded at equal density (5 X $10^4$ cells/well) in quadruplicate wells of 96-well flat bottom plates. Cells were incubated with 5% v/v LC for 24h, using a protocol based on a previous report (S1), then cell viability was determined using MTT assay (n=4)(*<0.05). S1. Hafeman S, C. London, R. Elmslie, S. Dow. 2010. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. *Cancer Immunol Immunother*. 59: 441-452.